From left to right : Vu H. Duong, M.D., Maria R. Baer, M.D., and Ashkan Emadi, M.D., Ph.D., specialists in the treatment of MDS in the Hematologic Malignancies Program at UMGCC
December 3, 2012: The University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) has been named a center of excellence for the treatment of myelodysplastic syndromes by the Myelodysplastic Syndromes (MDS) Foundation.
Myelodysplastic Syndromes are a group of bone marrow disorders in which the bone marrow does not produce enough healthy blood cells.
The center of excellence designation recognizes academic cancer centers that have particular expertise in treating patients with MDS, have available cytogenetics and/or molecular genetics resources, have published peer-reviewed publications in the field and offer patients access to clinical research trials investigating new approaches to the prevention, diagnosis and treatment MDS.
"This designation is an endorsement of our cancer centers outstanding clinical program in hematologic malignancies and in the exciting scientific research underway here to improve the lives of patients diagnosed with MDS and other blood cancers, says Kevin J. Cullen, M.D., director of the Marlene and Stewart Greenebaum Cancer Center.
For more information about the Greenebaum Cancer Center, go to www.umgcc.org or call 1-800-888-8823. To make an appointment with our cancer experts, please call 410-328-7904.
About the University of Maryland Greenebaum Cancer Center: The University of Maryland Marlene and Stewart Greenebaum Cancer Center is a National Cancer Institute-designated cancer center, and part of the University of Maryland Medical Center and the University of Maryland School of Medicine. It has comprehensive programs to treat all types of cancer and is a major referral center for patients throughout Maryland and the region. It has been recognized as one of the top 15 cancer centers in the nation by U.S. News & World Report in 2012-13.